1. Supply strategy
Depot footprint, shipping lanes, importer-of-record arrangements and permit pathways defined per country, with lead times built into the activation plan.
Solutions · Clinical Logistics | Clinical Supply Chain and Depot Management | Guosa Life Sciences
Integrated Clinical Logistics Supporting Every Study
Clinical logistics connects every component of a clinical trial, from investigational product distribution and biospecimen transport to temperature-controlled storage, customs clearance and site delivery.
Overview
Efficient logistics are essential to maintaining study timelines, participant safety and product integrity.
Guosa Life Sciences coordinates investigational products, laboratory specimens, medical devices, ancillary supplies and clinical documentation through secure, compliant, technology-enabled supply chains.

Capabilities
The GLS Advantage
Every solution delivered by Guosa Life Sciences is strengthened by the broader enterprise. Our operational teams are supported by evidence-based Insights, professional development through GLS Academy, collaborative partnerships within the Clinical Development Network and a quality-driven delivery model, enabling scientifically sound, operationally efficient and scalable solutions.
The capability
We move investigational product and study materials: depot selection and qualification, import and export permit management, customs clearance, controlled-temperature distribution to site, inventory and expiry management, and returns and destruction with documented reconciliation.
Our planning assumption is that the last mile is the hard part. Airport-to-depot is a solved problem in most markets; depot-to-site across distance, variable power and seasonal road conditions is where product is lost. We qualify the shipping lane end to end, specify packaging against the actual route rather than the nominal one, and instrument shipments so an excursion is detected in transit rather than discovered at the site.
Regulatory considerations
Import permits for investigational product are issued separately from the trial approval, frequently by a different authority, and on their own timeline. In several markets the permit is study-specific and shipment-specific, so a program that treats it as a one-time administrative step will stall at the second shipment. Customs classification and the identity of the importer of record must be settled before the first consignment moves, and establishing an importer-of-record arrangement in a new country carries a fixed cost largely independent of shipment volume.
Excursion handling is where documentation is most often found wanting. GDP-aligned distribution requires that every deviation from the specified temperature range is detected, recorded, assessed for product impact by a qualified person, and closed with a documented decision on whether the product remains usable. An excursion that was managed but not evidenced is, at inspection, indistinguishable from one that was ignored.
How an engagement runs
Depot footprint, shipping lanes, importer-of-record arrangements and permit pathways defined per country, with lead times built into the activation plan.
Depots audited, lanes qualified against the actual route, packaging specified and validated for the temperature profile and duration.
Instrumented shipments with in-transit monitoring, inventory and expiry management, and defined excursion assessment.
Returns, destruction and full accountability documentation at close-out.
What you receive
A country supply strategy with permit and importer-of-record mapping. Qualified depots and validated shipping lanes. Temperature records with documented excursion assessments. Full product accountability and destruction records.
Evidence and context
Our operating assumptions are published rather than asserted. The Future of Clinical Trials in Africa sets out why study performance is increasingly determined by ecosystem maturity rather than site selection, and The Untapped Advantage makes the case that institutions, not regions, are the right unit of qualification. Both are available in full, with executive briefs for readers who want the argument in a shorter form.
FAQ
Yes, cold-chain storage, temperature monitoring and validated distribution are core to our logistics services, including vaccines and biologics.
Yes. We coordinate customs clearance and import/export permits, particularly across complex multi-country and emerging-market programs.
Tell us about your objectives and our multidisciplinary team will scope an integrated, flexible solution.